In vivo protein transduction: delivery of a biologically active protein into the mouse - PubMed (original) (raw)
In vivo protein transduction: delivery of a biologically active protein into the mouse
S R Schwarze et al. Science. 1999.
Abstract
Delivery of therapeutic proteins into tissues and across the blood-brain barrier is severely limited by the size and biochemical properties of the proteins. Here it is shown that intraperitoneal injection of the 120-kilodalton beta-galactosidase protein, fused to the protein transduction domain from the human immunodeficiency virus TAT protein, results in delivery of the biologically active fusion protein to all tissues in mice, including the brain. These results open new possibilities for direct delivery of proteins into patients in the context of protein therapy, as well as for epigenetic experimentation with model organisms.
Comment in
- Introducing proteins into the body's cells.
Strauss E. Strauss E. Science. 1999 Sep 3;285(5433):1466-7. doi: 10.1126/science.285.5433.1466b. Science. 1999. PMID: 10498525 No abstract available.
Similar articles
- The kinetics and tissue distribution of protein transduction in mice.
Cai SR, Xu G, Becker-Hapak M, Ma M, Dowdy SF, McLeod HL. Cai SR, et al. Eur J Pharm Sci. 2006 Mar;27(4):311-9. doi: 10.1016/j.ejps.2005.10.011. Epub 2006 Jan 11. Eur J Pharm Sci. 2006. PMID: 16376528 - Introducing proteins into the body's cells.
Strauss E. Strauss E. Science. 1999 Sep 3;285(5433):1466-7. doi: 10.1126/science.285.5433.1466b. Science. 1999. PMID: 10498525 No abstract available. - Delivery of TAT/PTD-fused proteins/peptides to islets via pancreatic duct.
Klein D, Mendoza V, Pileggi A, Molano RD, Barbé-Tuana FM, Inverardi L, Ricordi C, Pastori RL. Klein D, et al. Cell Transplant. 2005;14(5):241-8. doi: 10.3727/000000005783983016. Cell Transplant. 2005. PMID: 16052906 - TAT-based drug delivery system--new directions in protein delivery for new hopes?
Rapoport M, Lorberboum-Galski H. Rapoport M, et al. Expert Opin Drug Deliv. 2009 May;6(5):453-63. doi: 10.1517/17425240902887029. Expert Opin Drug Deliv. 2009. PMID: 19413454 Review. - TAT-GDNF in neurodegeneration and ischemic stroke.
Kilic E, Kilic U, Hermann DM. Kilic E, et al. CNS Drug Rev. 2005 Winter;11(4):369-78. doi: 10.1111/j.1527-3458.2005.tb00054.x. CNS Drug Rev. 2005. PMID: 16614736 Free PMC article. Review.
Cited by
- Cationic Cell-Penetrating Peptides Are Potent Furin Inhibitors.
Ramos-Molina B, Lick AN, Nasrolahi Shirazi A, Oh D, Tiwari R, El-Sayed NS, Parang K, Lindberg I. Ramos-Molina B, et al. PLoS One. 2015 Jun 25;10(6):e0130417. doi: 10.1371/journal.pone.0130417. eCollection 2015. PLoS One. 2015. PMID: 26110264 Free PMC article. - Development of protein mimics for intracellular delivery.
deRonde BM, Tew GN. deRonde BM, et al. Biopolymers. 2015 Jul;104(4):265-80. doi: 10.1002/bip.22658. Biopolymers. 2015. PMID: 25858701 Free PMC article. Review. - Lessons from Recent Advances in Ischemic Stroke Management and Targeting Kv2.1 for Neuroprotection.
Yeh CY, Schulien AJ, Molyneaux BJ, Aizenman E. Yeh CY, et al. Int J Mol Sci. 2020 Aug 25;21(17):6107. doi: 10.3390/ijms21176107. Int J Mol Sci. 2020. PMID: 32854248 Free PMC article. Review. - Targeted disruption of Kv2.1-VAPA association provides neuroprotection against ischemic stroke in mice by declustering Kv2.1 channels.
Schulien AJ, Yeh CY, Orange BN, Pav OJ, Hopkins MP, Moutal A, Khanna R, Sun D, Justice JA, Aizenman E. Schulien AJ, et al. Sci Adv. 2020 Jul 1;6(27):eaaz8110. doi: 10.1126/sciadv.aaz8110. Print 2020 Jul. Sci Adv. 2020. PMID: 32937450 Free PMC article. - Protein kinase G inhibits flow-induced Ca2+ entry into collecting duct cells.
Du J, Wong WY, Sun L, Huang Y, Yao X. Du J, et al. J Am Soc Nephrol. 2012 Jul;23(7):1172-80. doi: 10.1681/ASN.2011100972. Epub 2012 Apr 19. J Am Soc Nephrol. 2012. PMID: 22518003 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources